Checkmate Pharmaceuticals
Cambridge, US · Founded 2015 · Delaware corporation · 4 known investors
Activating the immune system to recognize and destroy tumor cells. (NASDAQ: CMPI) (Acquired by Regeneron)
Founders & leadership
Checkmate Pharmaceuticals was founded in 2015 by Art Krieg.
AK
Art KriegFounder
BL
Barry LabingerExecutive
CA
Chuck AbdalianExecutive
DM
David MauroExecutive
KB
Karen BrennanExecutive
CY
Charles YonExecutive
Board
BA
Ben AuspitzBoard director
MP
Michael PowellBoard director
CG
Corey GoodmanBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$185.1M disclosed across 6 rounds · 2015–2020
▶$85.1MraisedJun 2020 · 17 investors · BiotechnologyRule 506(b)
▶$85.1MraisedJun 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James WooldridgeExecutive Officer
- Karen BrennanExecutive Officer
- Kleem ChaudharyExecutive Officer
- Robert WeisskoffDirector
- Jonathan LieberExecutive Officer
- Michael PowellDirector
- Barry LabingerExecutive Officer, Director
- Corey GoodmanDirector
- Peter ColabuonoDirector
- Keith FlahertyDirector
- Charles YonExecutive Officer
- Alan FuhrmanDirector
- Arthur KriegExecutive Officer, Director
- Offering amount
- $100.1M
- Amount sold
- $85.1M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$10MraisedApr 2020 · 4 investors · BiotechnologyRule 506(b)
▶$10MraisedApr 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles YonExecutive Officer
- James WooldridgeExecutive Officer
- Jonathan LieberExecutive Officer
- Arthur KriegExecutive Officer, Director
- Barry LabingerExecutive Officer, Director
- Keith FlahertyDirector
- Michael PowellDirector
- Corey GoodmanDirector
- Kleem ChaudharyExecutive Officer
- Alan FuhrmanDirector
- Karen BrennanExecutive Officer
- Peter ColabuonoDirector
- Robert WeisskoffDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$16MraisedJan 2020 · 4 investors · BiotechnologyRule 506(b)
▶$16MraisedJan 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barry LabingerExecutive Officer, Director
- Arthur KriegExecutive Officer, Director
- Robert WeisskoffDirector
- Jonathan LieberExecutive Officer
- Karen BrennanExecutive Officer
- James WooldridgeExecutive Officer
- Kleem ChaudharyExecutive Officer
- Charles YonExecutive Officer
- Michael PowellDirector
- Corey GoodmanDirector
- Keith FlahertyDirector
- Alan FuhrmanDirector
- Peter ColabuonoDirector
- Offering amount
- $16M
- Amount sold
- $16M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$22MraisedApr 2019 · 4 investors · BiotechnologyRule 506(b)
▶$22MraisedApr 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barry LabingerExecutive Officer, Director
- Ben AuspitzDirector
- Art KriegExecutive Officer, Director
- Chuck AbdalianExecutive Officer
- David MauroExecutive Officer
- Karen BrennanExecutive Officer
- Charles YonExecutive Officer
- Michael PowellDirector
- Corey GoodmanDirector
- Offering amount
- $22M
- Amount sold
- $22M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$27MraisedJun 2017 · 3 investors · BiotechnologyRule 506(b)
▶$27MraisedJun 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Corey GoodmanDirector
- David MauroExecutive Officer
- Ben AuspitzDirector
- Michael PowellDirector
- Charles YonExecutive Officer
- Charles AbdalianExecutive Officer
- Arthur M. KriegExecutive Officer, Director
- Ramani VaranasiExecutive Officer
- Offering amount
- $27M
- Amount sold
- $27M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$25MraisedFeb 2017 · 2 investors · BiotechnologyRule 506(b)
▶$25MraisedFeb 2017 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Corey GoodmanDirector
- Arthur A. KriegExecutive Officer, Director
- Michael PowellDirector
- Chuck AbdalianExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Checkmate Pharmaceuticals do?
- Activating the immune system to recognize and destroy tumor cells. (NASDAQ: CMPI) (Acquired by Regeneron)
- Who founded Checkmate Pharmaceuticals?
- Checkmate Pharmaceuticals was founded by Art Krieg in 2015.
- Who are Checkmate Pharmaceuticals's investors?
- Checkmate Pharmaceuticals's investors include F-Prime Capital, Sofinnova Ventures, Longitude Capital, Novo Holdings.
- How much funding has Checkmate Pharmaceuticals raised?
- Checkmate Pharmaceuticals has disclosed $185.1M raised across 6 rounds.
- Where is Checkmate Pharmaceuticals headquartered?
- Checkmate Pharmaceuticals is headquartered in Cambridge, US.